Tag Archives: sny

Regeneron Cholesterol-Drug Worries Ding Stock

Regeneron Pharmaceuticals (REGN) plunged 10% Friday afternoon after trading was briefly halted for volatility, after word got out that the FDA is investigating its cholesterol-drug candidate for adverse effects. The item was buried deep in a 20-F form Regeneron’s big-pharma partner Sanofi (SNY) filed Friday. Under a discussion of the two firms’ collaboration on alirocumab, a monoclonal antibody of a type called PCSK9 for treating high cholesterol,

Lilly Drug Ramucirumab Boosts Lung Cancer Survival

Big pharma Eli Lilly (LLY) said Wednesday that its drug candidate ramucirumab improved the survival of lung-cancer patients in a late-stage study. Lilly stock gapped up 3% in early trading on the stock market today. The study looked at patients with metastatics non-small-cell lung cancer (NSCLC) who had failed a previous round of platinum-based chemotherapy. One group of patients took standard cancer drug docetaxel (best known as Sanofi’s (SNY)

Cubist Antibiotic Shines In Trials; Stock Jumps

Cubist Pharmaceuticals (CBST) reported positive late-stage trial results for its antibiotic candidate Monday, sending Cubist stock to a 13-year high on the stock market today. The drug, ceftolozane/tazobactam, known in the industry as tol/taz for short, was tested in patients with urinary tract infections and compared to levofloxacin, which is known commercially as Johnson & Johnson’s (JNJ) Levaquin and Sanofi’s (SNY) Tavanic. Cubist said tol/taz